Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ELANE | P08246 | 3/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462417 | 1.00 | MAPT (0.48) | MAPTELANEGPR84ALOX15SMN1; SMN2 | |
| SCHEMBL5452446 | 1.00 | MAPT (0.48) | MAPTELANEGPR84ALOX15SMN1; SMN2 | |
| SCHEMBL4484148 | 0.94 | TLR8 (0.40) | MAPTELANEALOX15SMN1; SMN2HCAR2 | |
| SCHEMBL17082596 | 0.92 | MAPT (0.42) | MAPTELANEGPR84ALOX15SMN1; SMN2 | |
| SCHEMBL14645434 | 0.92 | MAPT (0.42) | MAPTELANEGPR84ALOX15SMN1; SMN2 | |
| SCHEMBL17082582 | 0.92 | MAPT (0.42) | MAPTELANEGPR84ALOX15SMN1; SMN2 | |
| SCHEMBL17082572 | 0.90 | MAPT (0.40) | MAPTELANEGPR84ALOX15SMN1; SMN2 | |
| SCHEMBL14430913 | 0.73 | MAPT (0.47) | MAPTELANEALOX15SMN1; SMN2TLR8 | |
| SCHEMBL5470194 | 0.71 | MAPT (0.45) | MAPTELANEALOX15SMN1; SMN2 | |
| SCHEMBL14430889 | 0.71 | MAPT (0.45) | MAPTELANEALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191373-A1 | Heterocyclic compounds for use in the treatment of viral infections | REGAN FOUNDATION (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191373-A1 | Heterocyclic compounds for use in the treatment of viral infections | REGAN FOUNDATION (BE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191373-A1 | Heterocyclic compounds for use in the treatment of viral infections | TPMT, TYMP, HAVCR2 | MAPT 3202/4885ELANE 1968/4885GPR84 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.